Member Info for Notposting

PIngu you have no evidence of any of that and appear to be making it up as you go along. I would suggest you don't and save the effort. I don't have an interest in your opinion.

Data is money. The goal isn’t to make a few hundred thousand a year, it is to use data to maximise success in the main trials and with the product candidate. That is the focus. They may find the mopey, I didn’t say to the contrary, but it is not a statement of fact as you put it. Most sadly won’t. I would also suggest refraining from personal comments, particularly when you don’t appear to know the difference between your and you’re.

It is a CDMO, a service, they do not need to, nor likely care about the data. This non binding partnership isn't a seal of approval, it is a paid service we are commissioning.

Pingu there is no evidence of this currently being a major interest in the US or overseas, which does not mean I don't agree the treatment could be if things progress successfully. I’m glad you agree that we should stick to the facts. The information I’ve shared comes directly from the CEO, so while you may choose to take a tunnel-visioned view, I don’t need to. My comments can be fact checked. Yours are personal and cannot.

Hemotruth, sadly it doesn't. That is what you appear to not understand. There will be strict conditions around it and it hasn't even been approved by the government, and anyone outside of Estonia would need to be able to afford such treatment. Try and be objective.

I like his honesty, but it's pending government approval as such. It appears the value here isn't in revenue as such but the data it will provide, if it proceeds.

He also believes in theory people from EU/ world could seek treatment, however as I’ve previously said there is strict criteria and this would like be extremely limiting.

It helps not to feed a narrative and be factual.

Misleading at best.

They approached a CDMO - it wasn’t Hemo that was sought out. This is simply a service arrangement (like going to VW to buy a car).

Capacity is limited given it’s a small company.

The potential market is around 20–40 patients, though not all will qualify, so the addressable market is even smaller.

Crucially, he does not claim it’s a cure. He only notes that if it proves curative, the data would be valuable.

Do elaborate on this rather dubious assertion, which appears less an objective assessment and more a convenient narrative to support an exit on your most recent trade. Describing it as a ‘self-funded pharma with multiple revenue-generating outcomes’ is, at best, misleading.

You mean you ‘bought back’ the ones you dumped while mindlessly ramping others into buying.

Just to clarify, I have no association with Alde and don’t intend to. Respectfully, some should recognise that this forum is quite small and doesn’t impact markets. The broader market ultimately reflects reality.

And where exactly have I “slagged” Hemo off? You mean provided a balance view? That to the contrary of others is based on the actual news not my agenda?

My comment was against CheckRicky as well, not Hemo on this occasion, but if it makes you happy hurling insults then you feel free.

Ramps continue, but I still haven’t seen any evidence of all of those purchases you mentioned yesterday and claimed to be making. Because there were none, were there CheckRicky?

CheckRicky. You still haven’t confirmed your purchases or “the kitchen sink.” Despite posting plenty of ramps, there’s no update - so as mentioned earlier, I’ll assume you haven’t bought anything and that your attempt to exit has failed.

You keep posting the same thing, yet you still haven’t shared your buys, nor the “kitchen sink” you claimed to be throwing at it this morning. That undermines your credibility.

Frankly, it looks like you haven’t bought a single share and that your real intention was simply to ramp the stock and lure others in so you could sell. If that was the plan, it’s good to see it didn’t work.

Still not listing those “buys” and the kitchen sink you’re throwing it at allegedly?

The fact I haven’t posted for six months would, if anything, suggest the opposite of a “lonely life.” Ironically, it wasn’t me digging through someone else’s posting history and making things personal just because I disagreed with their view.

As for what you call “negative” posts, many would see them as balanced and fact-based rather than hype. I’m sorry if that doesn’t suit your agenda, much like others here who seem more focused on talking their exit strategy than discussing the market itself.

At the end of the day, the market is far bigger than any of us. Its reaction speaks louder than any individual opinion, and right now it is ratifying one perspective far more strongly than the majority here. That is what is truly telling, and that is what people should focus on.

Any update on those buys you said you’d be making? Or was that just a ramp while you offload some instead?

“This is commercialisation and definately revenue” - it is non binding and there isn’t definite anything nor is it commercialisation at this time.

Except they can’t. Only a limited patient data set qualifies, and suggesting otherwise is misleading. Nor is it currently possible, as there are still significant challenges to overcome.